Shots:

• The acquisition is focus on development of vaccines for adenovirus types 4 and 7- and expanding the company’s vaccine product portfolio
• Emergent to pay an upfront ~$270M in cash to get hold of PaxVax’s two marketed vaccines- Vivotif and Vaxchora and pipeline products
• Vivotif (Typhoid Vaccine Live Oral Ty21a)- and Vaxchora (Cholera Vaccine- Live- Oral) are novel vaccines approved by the US FDA for the prevention of typhoid fever and for prevention of cholera respectively

Ref: Emergent Biosolutions  | Image: PaxVax